CAPR ▲ +2.2% - Capricor Therapeutics, Inc. $CAPR u/g Overweight @ Piper pt 25 Capricor Therapeutics rose 2.2% following an upgrade to Overweight by Piper Sandler, which set a price target of $25 on the stock. The upgrade and target price provided a near-term catalyst for the modest gains. 01-SEP-2026 05:16 AM ET